UPDATE 1-Valeant picks up AstraZeneca psoriasis drug after Amgen exit

Sept 1 (Reuters) - Canada's Valeant Pharmaceuticals International Inc is buying rights to AstraZeneca Plc's late-stage experimental psoriasis drug brodalumab after it was dropped by Amgen Inc in May.